纳洛酮联合血必净治疗感染性休克的临床疗效及作用机制研究  

Clinical effects of naloxone hydrochloride combined with xuebijing on septic shock

作　　者：邢正云[1] 冯国安[2] 

机构地区：[1]大丰市人民医院ICU,江苏大丰224100 [2]大丰市人民医院血液科

出　　处：《临床急诊杂志》2011年第6期388-390,共3页Journal of Clinical Emergency

摘　　要：目的:观察纳洛酮联合血必净治疗感染性休克的临床疗效,并探讨其可能的作用机制。方法:对45例感染性休克患者,随机分为2组,治疗组23例,对照组22例,治疗组患者在常规抗休克治疗的基础上加用纳洛酮联合血必净治疗。结果:治疗组总有效率为91.3%,明显好于对照组72.7%(P<0.05),监测血液动力学变化△CVP、△MAP、△UA、△ScvO2治疗组明显好于对照组(P<0.05)。治疗组MODS的发生率为30.4%(7/23)。病死率为13.0%(3/23),对照组MODS的发生率为54.6%(12/22),病死率为27.3%(6/22),两组MODS的发生率比较差异有统计学意义(P<0.05)。结论:纳洛酮联合血必净能够显著改善感染性休克患者的病情,提高生存率。作用机制可能与纳洛酮能拮抗β内啡肽,血必净能降低内毒素的水平有关。Objective:To observe the clinical therapeutic effects of Naloxone Hydrochloride for Injection Combined with Xuebijing on septic shock.Method:45 cases of septic shock were randomly into therapeutic group(23 cases) and control group(22 cases) . The therapeutic group was treated with naloxone hydrochloride and Xuebijing. Control group only received basic therapy.Result:The overall response rates were 91.3% in therapeutic group and 72.7% in control group(P<0.05) . The hemodynamic variety CVP,MAP,UA,ScvO2,MODS of the therapeutic group was significantly improved than that of control group.Conclusion:Combinational treatment of Naloxone Hydrochloride and Xuebijing significantly improved severity of septic shock and survival rate.

关 键 词：感染性休克 纳洛酮 血必净 

分 类 号：R364.1[医药卫生—病理学]